Lucentis beats Visudyne in trial

In a head-to-head trial against Novartis' own drug Visudyne, Novartis and partner Genentech's experimental drug Lucentis was found to be more effective in preventing age-related vision loss. Ninety-five percent of patients taking Lucentis had vision levels that stayed steady or improved after one year, as compared to the 64 percent taking Novartis' Visudyne. This was the second phase III trial of the drug.

- read this press release for more